BridgeBio Pharma (BBIO) vs Jazz Pharmaceuticals (JAZZ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Jazz Pharmaceuticals (JAZZ) has outperformed BridgeBio Pharma (BBIO) over the past year, gaining 69.9% versus a gain of 22.6%. Over five years, JAZZ leads with a +64.3% price change compared with +38.6% for BBIO. Jazz Pharmaceuticals is the larger company by market cap ($15.01 billion vs $13.00 billion), about 1.2 times the size, while BridgeBio Pharma is growing revenue faster (+126.3% vs +4.9%).
On valuation, Jazz Pharmaceuticals trades at a lower forward P/E (8.9x vs 2420.8x for BridgeBio Pharma). Jazz Pharmaceuticals converts more of its revenue into profit, with a net margin of -8.3% versus -146.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BBIO | JAZZ |
|---|---|---|
| Share price | $66.50 | $231.19 |
| Market cap | $13.00B | $15.01B |
| 1-day change | -0.69% | -0.09% |
| YTD return | -13.06% | +37.22% |
| 1-year return | +22.65% | +69.88% |
| 5-year return | +38.60% | +64.31% |
| P/E ratio (TTM) | — | 15.85 |
| Forward P/E | — | 8.93 |
| EPS (TTM) | $-3.56 | $14.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $502.08M | $4.27B |
| Revenue growth (YoY) | +126.26% | +4.88% |
| Net income (latest FY) | $-732.94M | $-356.15M |
| Gross margin | 95.82% | — |
| Operating margin | -104.25% | -10.08% |
| Net margin | -145.98% | -8.35% |
| 52-week high | $93.42 | $266.38 |
| 52-week low | $52.75 | $128.80 |
| Distance from 52-week high | -28.81% | -13.21% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +63.98% | +27.38% |
| Average volume | 2.75M | 854.88K |
| Shares outstanding | 195.49M | 64.91M |
| Employees | 999 | 2,890 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- JAZZ has outperformed BBIO by 47.2 percentage points over the past year.
- Jazz Pharmaceuticals is more profitable, keeping -8.3 cents of every revenue dollar as net income versus -146.0 cents for BridgeBio Pharma.
- BridgeBio Pharma grew revenue faster in its latest fiscal year (+126.26% vs +4.88%).
About BridgeBio Pharma
BBIO stock →BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia.
Health Care · Biotechnology: Pharmaceutical Preparations · 999 employees
About Jazz Pharmaceuticals
JAZZ stock →Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,890 employees
BBIO vs JAZZ FAQ
Which is bigger, BridgeBio Pharma or Jazz Pharmaceuticals?
Jazz Pharmaceuticals (JAZZ) is larger, with a market capitalization of $15.01B compared with $13.00B for BridgeBio Pharma (BBIO).
Which stock has performed better over the past year, BBIO or JAZZ?
JAZZ returned +69.88% over the past 12 months, compared with +22.65% for BBIO (price return, excluding dividends). Past performance does not predict future results.
Are BridgeBio Pharma and Jazz Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.